Inaktiver Wert

Andere Sprachen Egalet Corp Nasdaq

Aktien

US28226B1044

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

ZYLA LIFE SCIENCES : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	20.05.20
ZYLA LIFE SCIENCES : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)	20.05.20
Zyla Life Sciences Repaid All Outstanding Indebtedness and Terminated the Commitment Under its Revolving Credit Agreement	20.05.20
Assertio and Zyla Life Sciences Announces Board Appointments to Combined Company	20.05.20
Assertio Therapeutics, Inc. completed the acquisition of Zyla Life Sciences.	20.05.20
ZYLA LIFE SCIENCES : Other Events, Financial Statements and Exhibits (form 8-K)	15.05.20
ZYLA LIFE SCIENCES : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	15.05.20
ZYLA LIFE SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14.05.20
Zyla Life Sciences Reports Earnings Results for the First Quarter Ended March 31, 2020	14.05.20
Zyla Life Sciences : to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results on May 15, 2020	01.05.20
Zyla Life Sciences : Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus	20.04.20
ZYLA LIFE SCIENCES : Change in Directors or Principal Officers, Other Events (form 8-K)	13.04.20
ZYLA LIFE SCIENCES : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	27.03.20
ZYLA LIFE SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	26.03.20
Zyla Life Sciences Reports Earnings Results for the Full Year Ended December 31, 2019	26.03.20
Zyla Life Sciences Auditor Raises 'Going Concern' Doubt	26.03.20
Zyla Life Sciences and Assertio Therapeutics Announce Management Appointments	17.03.20
Assertio Therapeutics, Inc. entered into an agreement to acquire Zyla Life Sciences for $20.9 million.	16.03.20
Zyla Life Sciences : to Host Conference Call and Webcast to Discuss Year End 2019 Financial Results on March 27, 2020	13.03.20
ZYLA LIFE SCIENCES : Entry into a Material Definitive Agreement, Other Events (form 8-K)	28.01.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Egalet Corp Nasdaq

Aktien

US28226B1044

Andere Sprachen

Filter